Williams v. Daiichi Sankyo, Inc.

947 F. Supp. 2d 1234, 2013 WL 2249078, 2013 U.S. Dist. LEXIS 70920, 118 Fair Empl. Prac. Cas. (BNA) 840
CourtDistrict Court, N.D. Alabama
DecidedMay 20, 2013
DocketNo. 2:11-CV-3629-KOB
StatusPublished
Cited by1 cases

This text of 947 F. Supp. 2d 1234 (Williams v. Daiichi Sankyo, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Alabama primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Williams v. Daiichi Sankyo, Inc., 947 F. Supp. 2d 1234, 2013 WL 2249078, 2013 U.S. Dist. LEXIS 70920, 118 Fair Empl. Prac. Cas. (BNA) 840 (N.D. Ala. 2013).

Opinion

MEMORANDUM OPINION

KARON OWEN BOWDRE, District Judge.

This matter comes before the court on Defendant Daiichi Sankyo, Inc.’s “Motion for Summary Judgment.” (Doc. 45). Plaintiff Ross Williams claims that DSI discriminated against him on the basis of his gender and retaliated against him because another DSI employee, District Manager Philip Lamb, filed an EEOC Charge against DSI. DSI argues that no genuine issue of material fact exists and that it is entitled to judgment as a matter of law on Mr. Williams’ discrimination and retaliation claims. DSI argues that no genuine issue of material fact exists and that it is entitled to judgment as a matter of law on Plaintiff Ross Williams’ two remaining claims before the court. For the following reasons, the court agrees with the Defendant and will GRANT its motion for summary judgment in its entirety and DISMISS WITH PREJUDICE Mr. Williams’ claims against DSI.

I. STATEMENT OF FACTS

A. Factual Background

1. Mr. Williams’ Employment at DSI

On January 7, 2008, Mr. Williams began working as a pharmaceutical sales representative for DSI in the Birmingham District, and DSI terminated Mr. Williams on November 4, 2008. DSI trained Mr. Williams for this position at the outset of his employment. Pharmaceutical sales representatives, like Mr. Williams, pro[1238]*1238mote DSI’s drugs primarily by visiting the offices of doctors who may prescribe DSI’s drugs, explaining the advantages of particular drugs, and providing samples of DSI drugs for doctors to give to their patients. Sales representatives’ salaries are based in part on incentive compensation earned from sales and sales ranking. DSI alleges that the distribution of samples is a “critical responsibility” of its sales representatives and that DSI sales representatives in Birmingham are expected to make eight to ten calls to doctors’ offices a day and deliver samples of DSI drugs on 60-80% of their calls. (Doc. 46, at ¶ 8; Doc. 47-6, at ¶ 12).

Mr. Williams, however, stated in his affidavit that during his training at DSI he was “instructed not to distribute samples of DSI drugs to doctors unless they requested them.” (Doc. 60-2, at ¶ 6). Mr. Williams also asserted that he was “never told to sample 60-80 percent” of his office calls until October 1, 2008 and that he was “never told by DSI management or employees that making 8 to 10 calls and distributing samples was a critical job performance criteria that could lead to [his] termination.” (Doc. 60-2, at ¶ 12-15). However, Mr. Williams does not dispute that he sent an e-mail on July 10, 2008 to Kerri Colvin, his Regional Director, acknowledging that he knew the 60-80% sampling guideline. (Doc. 47-4, at 32). Mr. Williams does not dispute that from the time he was hired in January 2008 until June 30, 2008 he only distributed samples to doctors during two weeks.

DSI alleges that it gave Mr. Williams a document entitled “[Southeast] Area Representative Expectations,” and that Mr. Williams was expected to meet those expectations. Those expectations included:

• utilize the computer in the field daily for reviewing pre-call planning and enter post-call notes
• enter and synchronize calls daily
• sample in accordance with Management’s description
• consistently adhere to all district, regional, and corporate deadlines
• electronically submit expense reports by the 4th of each month
• submit budget trackers monthly
• mail sample distribution forms weekly
• adhere to DSI’s [standards of procedure] and Compliance Guidelines

(Doc. 47-4, at 26-27). Mr. Williams alleges that he did not receive this document until October 2008, shortly before he was terminated. (Doc. 60-2, at ¶ 12). However, in his deposition and emails sent to various DSI supervisors, Mr. Williams demonstrated an understanding of most, if not all, of these documenting and compliance expectations during his employment at DSI.

The parties do not dispute that it is “crucial” that sales representatives document and inventory the distribution and transfer of their samples to comply with FDA regulations. When sales representatives distribute samples to doctors, they must complete a sample distribution form (“SDF”), and sales representatives must submit all SDFs to DSI weekly. Mr. Williams did not submit a single SDF from July 25, 2008 to September 26, 2008.

From January 2008 to May 2008, District Manager Philip Lamb supervised Mr. Williams, and after Mr. Lamb was discharged in May 2008, Kerri Colvin, a Regional Director, supervised Mr. Williams until Kim Mitchell was hired as a District Manager in September 2008.

On July 1, 2008, Colvin spoke to Mr. Williams regarding delinquent SDFs and sample inventory forms. Mr. Williams stated that his SDFs were ready to submit and that his sample inventory form would be ready on the following morning. Mr. Williams told Colvin that his failure to [1239]*1239submit his calls daily was due to a problem with the EDGE database that interfaces with DSI sales representatives’ laptops to allow them to upload their call logs daily. On July 2, 2008, Colvin still had not received any of Mr. Williams’ delinquent documents and e-mailed Mr. Williams to instruct him to submit his sample inventory by the close of business. In the e-mail, Colvin also reminded Mr. Williams that failure to comply with the sample policies and procedures could lead to disciplinary action up to and including termination. Mr. Williams responded to the e-mail acknowledging the delinquent documents and stating “I absolutely understood the procedure and expectations, and am truly sorry about any delays .... you won’t see my name on any ‘bad’ lists from this point on.” (Doc. 47-1, at 8).

On July 9, 2008, Colvin sent Mr. Williams an e-mail asking why he had failed to submit his weekly SDFs for ten weeks during April to June 2008 and instructed Mr. Williams to submit copes of all remaining SDFs to the regional office by Monday July 14, 2008. Mr. Williams responded to Colvin stating that he had only distributed samples for two weeks during April to June 2008 but had “made corrections in [his] day to day action” since he had a discussion with Colvin about the importance of sampling. (Doc. 47-4, at 32). Williams also stated in the e-mail that all of his calls from April 18, 2008 to July 7, 2008 were missing from the EDGE database but that he currently had the capability to sync through EDGE going forward.

Colvin forwarded Mr. Williams’ e-mail to Karie Thoma, a Sample Compliance Analyst, and Brian Hauser, East Regional Director, with her recommendation that DSI issue a “sternly worded coaching letter” to Mr. Williams. (Doc. 47-4, at 31). On July 14, 2008, Thoma replied to Colvin expressing concern over Mr. Williams’ “explanation of events” and specifically his EDGE synchronization issue and lack of paperwork, but Thoma did not discuss whether a coaching letter should be sent to Mr. Williams. Id. Thoma requested Randy Labak, Senior Manager of Sales Force Automation, review Mr. Williams’ reported EDGE synching problems.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
947 F. Supp. 2d 1234, 2013 WL 2249078, 2013 U.S. Dist. LEXIS 70920, 118 Fair Empl. Prac. Cas. (BNA) 840, Counsel Stack Legal Research, https://law.counselstack.com/opinion/williams-v-daiichi-sankyo-inc-alnd-2013.